Navigation Links
Lifelong Antiretroviral Treatment for HIV-Infected Pregnant Women Prevents Infection in Children, Saves Mothers' Lives, Study Finds
Date:3/12/2013

BETHESDA, Md., March 12, 2013 /PRNewswire/ -- Providing life-long antiretroviral treatment to HIV-infected pregnant women not only prevents HIV infections in infants, but also improves the 10-year survival rate in mothers, saving more than 250,000 maternal life years and reducing the likelihood that children born to these mothers will become orphans, a study published today in the journal PLOS ONE found.

Transmission of HIV during pregnancy, labor, delivery or breastfeeding is the main mode of HIV infection in children. An estimated 390,000 children worldwide acquired HIV from their mothers in 2010, with more than 90 percent of these new infections occurring in sub-Saharan Africa. Malawi, a low-income country of 15 million people, is one of the countries with the highest number of HIV-infected pregnant women.

The study from Abt Associates' Dr. Carlos Avila and colleagues examined how the Ministry of Health in Malawi is implementing a new program termed Option B+, in which all pregnant women who test HIV positive are placed on antiretroviral therapy (ART) for life, regardless of their CD4 count or clinical stage.

They looked at whether the program represents a cost-effective policy option for treating HIV-infected pregnant women and for preventing mother-to-child transmission, as compared with World Health Organization guidelines (Option A and B) to prevent mother-to-child transmission of HIV. Those guidelines recommend antiretroviral therapy for women with CD4 counts at or lower than 350 cells per microliter, which presents a major restriction in areas where lab resources are scarce. Under WHO Option A, the mother receives antiretrovirals at three different stages of pregnancy and then for a week after childbirth. Under WHO Option B, the mother takes a triple antiretroviral regimen at 14 weeks, and continues taking this treatment until the child is born. Antiretrovirals are suspended after delivery, or one week after all infant exposure to breast milk has ended. The infants receive antiretroviral prophylaxis.

Researchers used data from Malawi to simulate the progression of HIV among a group of HIV-infected pregnant women who received preventive and antiretroviral therapy, and estimated the number of pediatric infections averted and maternal life years gained over a 10-year period. They found that providing lifelong antiretroviral treatment to all mothers would improve 10-year survival in mothers more than four-fold, saving more than 250,000 maternal life years, as compared to mothers receiving other treatment options, which saved 153,000 and 172,000 life years respectively. In addition, providing ARTs for all HIV-infected pregnant women could save $455 U.S. per life year gained.

"Although providing these drugs may cost more in the short term, it will save many lives, prevent future infant infections and reduce the chances that a child will become an orphan in the long term," said Avila, a senior health economist at Abt. "This study takes into account the realities of providing antiretrovirals in rural Africa, where lab facilities are scarce and requirements to start treatment based on CD4 counts are a major impediment to mothers getting the treatment they need."

The researchers also note that simplifying drug regimen options may improve adherence to therapy and can help overcome some of the individual, organizational and societal barriers to achieving high coverage levels of prophylaxis and treatment.

For the full paper, please visit: http://dx.plos.org/10.1371/journal.pone.0057778

About Abt Associates
Abt Associates is a mission-driven, global leader in research and program implementation in the fields of health, social and environmental policy, and international development. Known for its rigorous approach to solving complex challenges, Abt Associates is regularly ranked as one of the top 20 global research firms and one of the top 40 international development innovators. The company has multiple offices in the U.S. and program offices in nearly 40 countries. www.abtassociates.com


'/>"/>
SOURCE Abt Associates
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa
2. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
3. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
4. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
5. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
6. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
7. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
8. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
9. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
10. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
11. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
Breaking Medicine News(10 mins):